3 most recent filings and news items mentioning TTRX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/TTRX/news?limit=20"
Pull TTRX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayTurn Therapeutics announced interim analysis results from its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, showing 92.6% of treated subjects achieved 50% eczema severity reduction within 4 weeks with no serious adverse events. The positive efficacy and safety
View filing at SEC.gov →Turn Therapeutics announced publication of a peer-reviewed study in the Journal of Dermatological Treatment demonstrating GX-03's efficacy in an IL-36-associated inflammatory dermatitis model with statistically significant disease severity reduction. The publication supports the
View filing at SEC.gov →Turn Therapeutics announced its CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. The company's lead candidate GX-03 is in Phase 2 trials for atopic dermatitis with topline results expected mid-2026.
View filing at SEC.gov →